NASDAQ:SABS - SAB Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: 17.00
  • Forecasted Upside: 745.77 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
2.01
▲ +0.01 (0.50%)

This chart shows the closing price for SABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SAB Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SABS

Analyst Price Target is 17.00
▲ +745.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is 17.00, with a high forecast of 0.00 and a low forecast of 0.00. The average price target represents a 745.77% upside from the last price of 2.01.

This chart shows the closing price for SABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in SAB Biotherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Chardan CapitalLower Price Target$10.00 ➝ $7.00High
4/1/2022Chardan CapitalLower Price TargetBuy$17.00 ➝ $10.00Low
12/2/2021Northland SecuritiesBoost Price TargetOutperform$18.00 ➝ $21.00High
11/25/2021Robert W. BairdReiterated RatingBuy$23.00High
11/5/2021Chardan CapitalInitiated CoverageBuy$17.00Low
11/1/2021Robert W. BairdInitiated CoverageOutperform$23.00High
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/18/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/20/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
SAB Biotherapeutics logo
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Read More

Today's Range

Now: 2.01
Low: 1.77
High: 2.23

50 Day Range

MA: 2.39
Low: 1.78
High: 3.76

52 Week Range

Now: 2.01
Low: 1.61
High: 12.90

Volume

25,000 shs

Average Volume

183,917 shs

Market Capitalization

$86.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of SAB Biotherapeutics?

The following equities research analysts have issued research reports on SAB Biotherapeutics in the last twelve months: Chardan Capital, Northland Securities, Robert W. Baird, and Zacks Investment Research.
View the latest analyst ratings for SABS.

What is the current price target for SAB Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for SAB Biotherapeutics in the last year. Their average twelve-month price target is 17.00, suggesting a possible upside of 745.8%.
View the latest price targets for SABS.

What is the current consensus analyst rating for SAB Biotherapeutics?

SAB Biotherapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SABS will outperform the market and that investors should add to their positions of SAB Biotherapeutics.
View the latest ratings for SABS.

How do I contact SAB Biotherapeutics' investor relations team?

SAB Biotherapeutics' physical mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The company's listed phone number is 305-204-3338 and its investor relations email address is [email protected] The official website for SAB Biotherapeutics is www.bigcypressaccorp.com. Learn More about contacing SAB Biotherapeutics investor relations.